ALEXANDRIA, Va., March 17 -- United States Patent no. 12,577,231, issued on March 17, was assigned to GlaxoSmithKline Intellectual Property Development Ltd. (Stevenage, Great Britain).
"Androgen receptor PROTACS" was invented by Christopher Patrick Tinworth (Stevenage, Great Britain) and Laura Trulli (Madrid).
According to the abstract* released by the U.S. Patent & Trademark Office: "Certain Androgen receptor PROTAC (PROteolysis TArgeting Chimera) compounds contain a series of 2,4-dioxotetrahydropyrimidinyl derivatives that bind cereblon. The PROTAC compounds may be viewed as being comprised of an androgen receptor binding moieties, a linker and a cereblon binding moiety or degron. Medical uses of these PROTAC compounds are also disclose...